Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Lambert

Showing results (1-10 of 167) with videos related to

Pageof 17
Sort By:
Evidence-Based Mental Health|August 23, 2011
Review: lack of evidence for the optimal dose of risperidone for schizophreniaMartin Lambert
Psychiatrische Praxis|July 3, 2015
[Editorial]Martin Härter, Martin Lambert
CNS Drugs|July 15, 2009
The CATIE and CUtLASS studies in schizophrenia: results and implications for cliniciansDieter Naber, Martin Lambert
Progress in Neuro-Psychopharmacology & Biological Psychiatry|December 14, 2004
Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanismDieter Naber, Martin Lambert
CNS Drugs|October 6, 2004
Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of lifeMartin Lambert, Dieter Naber
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|October 8, 2013
Should we listen and talk more to our patients?Dieter Naber, Martin Lambert
Der Nervenarzt|September 5, 2019
[Healthcare research in the living environment]Martin Lambert, Anne Karow, Jürgen Gallinat
Psychiatrische Praxis|December 9, 2004
[Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease]Dieter Naber, Martin Lambert, Anne Karow
Expert Opinion on Pharmacotherapy|August 2, 2008
Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictorsChristian G Huber, Dieter Naber, Martin Lambert
Expert Opinion on Pharmacotherapy|August 2, 2008
Management of incomplete remission and treatment resistance in first-episode psychosisMartin Lambert, Dieter Naber, Christian G Huber
Pageof 17

Showing results (1-10 of 167) with videos related to

Sort By:
Pageof 17
Evidence-Based Mental Health|August 23, 2011
Review: lack of evidence for the optimal dose of risperidone for schizophreniaMartin Lambert
Psychiatrische Praxis|July 3, 2015
[Editorial]Martin Härter, Martin Lambert
CNS Drugs|July 15, 2009
The CATIE and CUtLASS studies in schizophrenia: results and implications for cliniciansDieter Naber, Martin Lambert
Progress in Neuro-Psychopharmacology & Biological Psychiatry|December 14, 2004
Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanismDieter Naber, Martin Lambert
CNS Drugs|October 6, 2004
Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of lifeMartin Lambert, Dieter Naber
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|October 8, 2013
Should we listen and talk more to our patients?Dieter Naber, Martin Lambert
Der Nervenarzt|September 5, 2019
[Healthcare research in the living environment]Martin Lambert, Anne Karow, Jürgen Gallinat
Psychiatrische Praxis|December 9, 2004
[Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease]Dieter Naber, Martin Lambert, Anne Karow
Expert Opinion on Pharmacotherapy|August 2, 2008
Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictorsChristian G Huber, Dieter Naber, Martin Lambert
Expert Opinion on Pharmacotherapy|August 2, 2008
Management of incomplete remission and treatment resistance in first-episode psychosisMartin Lambert, Dieter Naber, Christian G Huber
Pageof 17